Samsung Bioepis became the first company to receive approval for a Lucentis biosimilar in Korea with ‘Amelivu (ranibizumab).’ Lucentis is a treatment developed by Genetech for ophthalmologic diseases such as macular degeneration and macular edema.

With Amelivu’s approval, Samsung Bioepis is now approved for a total of 6 biosimilars in Korea. The company is selling 3 types of autoimmune disease treatments that treat rheumatoid arthritis, etc – ‘Etoloce (Enbrel similar),’ ‘Remaloce (Remicade similar),’ and ‘Adaloche (Humira similar)’ – with Yuhan Corp. Its other two drugs, which are anticancer drugs ‘Sampenet (Herceptin similar),’ and ‘Onbevzi (Avastin similar)’ are sold jointly w